期刊文献+

不同剂量阿托伐他汀在冠脉介入治疗围手术期的应用研究 被引量:6

Application of different doses of atorvastatin in percutaneous coronary intervention treatment during perioperative period
下载PDF
导出
摘要 目的:探讨不同剂量的阿托伐他汀在经皮冠脉介入治疗(PCI)围手术期应用的价值。方法:120例拟行(PCI)的冠心病(CHD)患者随机分为对照组(A组)、低剂量干预治疗组(B组)和中等剂量干预治疗组(C组)。A组术前不服用阿托伐他汀,B和C组术前分别服用20mg或40mg阿托伐他汀7d,3组患者术后均用阿托伐他汀20mg/d维持治疗。术前、术后24h及术后1月后监测CK-MB、C反应蛋白、肌钙蛋白I、血肌酐。结果:(1)PCI术后24hCK-MB、C反应蛋白较术前均有升高,A组与B、C组差异有统计学意义(P<0.05),B和C组间差异无统计学意义(P>0.05),术后1月A组CK-MB、C反应蛋白与B组、C组差异有统计学意义(P<0.05);(2)B、C组患者围手术期MI发生率较A组低,但差异无统计学意义(P>0.05);(3)3组患者血肌酐的变化差异均无统计学意义(均P>0.05)。结论:PCI术后CK-MB、C反应蛋白水平升高,提示存在一定的PCI术相关性心肌损伤;PCI术前阿托伐他汀干预治疗7天也可以在一定程度抑制PCI相关心肌损害,未显示有肾保护作用。 Objective: To evaluate the value of different doses of atorvastatin in percutaneous coronary intervention(PCI) treatment during perioperative period.Methods: A total of 120 CHD patients scheduled for PCI treatment were randomly divided into control group(group A),low-dose intervention group(group B) and middle-dose intervention group(group C).Group A didn't take atorvastatin during perioperative period,while group B and C took atorvastatin at does of 20 and 40 mg,respectively for 7 days before undergoing the surgery.All the three groups were given postoperative atorvastatin 20 mg/d as maintenance therapy.Monitor CK-MB,C-reactive protein,troponin I,and serum creatinine 24 hours before and after the surgery as well as 1 month after the surgery.Results:(1) The CK-MB,C-reactive protein increased 24 hours after the PCI treatment in all groups,but the increase was significantly different in group A than that in group B and C(P0.05),significant difference in increases of CK-MB,C-reactive protein was observed between group B and C 1 month after the surgery(P0.05),though no similar result was shown before(P0.05).(2) Group B and C showed lower incidence of perioperative MI was than group A,but the difference was not statistically significant(P 0.05)(3) Changes in serum creatinine level were not significant in all three groups(P0.05).Conclusions: The postoperative increase of CK-MB,C-reactive protein suggests occurrence of PCI related myocardial damage;taking atorvastatin for 7 days before undergoing CPI treatment can inhibited this damage to some extent as well as produce renal protective effects.
出处 《海南医学院学报》 CAS 2012年第6期830-832,共3页 Journal of Hainan Medical University
基金 中国高校医学期刊临床专项资金项目(112210202)~~
关键词 阿托伐他汀 经皮冠状动脉介入治疗 心肌保护 Atorvastatin Percutaneous coronary intervention Myocardial protection
  • 相关文献

参考文献6

  • 1霍勇.PCI围手术期强化他汀治疗:从证据到实践[J].心血管病学进展,2009,30(4):546-549. 被引量:5
  • 2Dibra A, Mehiili J, Braun S, et al. Inflammatory re- sponse after intervention assessed by serial C-reactive protein measurements correlates with restenosis in pa- tients treated with coronary stenting[J]. Am Heart J, 2005,150 (2), 344-350.
  • 3Ray KK,Cannon CP. The potential relevance ofthe mul- tiple lipidindependent(pleotropic)effects of statins in the managment of acute coronarysyndromes[J].J Am Coil Cardiol, 2005,46(8), 1425-1433.
  • 4L indsay J ,Apple S, Pinnow EE, et al. Percutaneous coronary intervention2asso2 ciated nephropathy fore- shadows increased risk of late adverse events in patients with normal baseline serum ereatinin[J].Catheter Cardiovasc Interv, 2003,59 : 338-343.
  • 5Rihal CS, Textor SC, GrillDE, et al. Incidence and p rognostic importance of acute renal failure after percuta- neous coronary intervention[J].Circulation, 2002, 105 : 2259-2264.
  • 6Zhao JL, Yang YJ 0 Zhang YH, et al. Effect of statins on contrast2induced nephropathy in patientswith acute myocardial infarction treated with primary an2 giop las- ty[J]. Int J Cardiol, 2008, 126: 435-436.

二级参考文献32

  • 1Plosker GL,Lysang-Williams KA.Clopidogrel:a review of its use in the prevention of thrombosis[J].Drugs,2007,67(4):613-646.
  • 2Kemis SJ,Harjai KJ,Stone GW,et al.Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty[J]?J Am Coll Cardiol,2004,43:1773-1779.
  • 3LaRosa JC,Grundy SM,Waters DD,et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J].N Engl J Med,2005,352:1425-1435.
  • 4Hermann J.Peri-procedural myocardial injury:2005 update[J].Eur Heart J,2005,26:2493-2519.
  • 5Abdelmeguid AE,Topol EJ,Whitlow PL,et al.Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions[J].Circulation,1996,94:1528-1536.
  • 6Brener SJ,Ellis SG,Schneider J,et al.Frequency and long-term impact of myonecrosis after coronary stenting[J].Eur Heart J,2002,23:869-876.
  • 7Stone GW,Mehran R,Dangas G,et al.Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention:a device-specific analysis of 7 147 patients[J].Circulation,2001,104:642-647.
  • 8Saucedo JF,Mehran R,Dangas G,et al.Long-term clinical events following creatine kinase-myocardial band isoenzyme elevation after successful coronary stenting[J].J Am Coll Cardiol,2000,35:1134-1141.
  • 9Briguoria C,Colombob A,Airoldi F,et al.Statin administration before percutaneous coronary intervention:impact on periprocedural myocardial infarction[J].Eur Heart J,2004,25:1822-1828.
  • 10Pasceri V,Patti G,Nusca A,et al.Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention:results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study[J].Circulation,2004,110:674-678.

共引文献4

同被引文献71

  • 1雷蕾,张熙洋,崔立芹,王意忠,贾晓琳.阿托伐他汀和瑞舒伐他汀对2型糖尿病血脂和高敏C反应蛋白作用效果的比较[J].中华临床医师杂志(电子版),2012,6(19):6049-6051. 被引量:18
  • 2汪晓红,黎汝,李莉.2型糖尿病合并急性心肌梗死患者血清内脂素水平及阿托伐他汀钙的干预作用[J].中国老年学杂志,2014,34(12):3225-3226. 被引量:11
  • 3马承恩,王可富,公茂磊,隋树建.急性冠状动脉综合征患者急性期血凝状态及抗凝治疗的影响[J].中华老年医学杂志,2007,26(7):492-494. 被引量:2
  • 4Schoonjans K, Peinado-Onsurbe J, Fruchart JC, et al. 3-Hydroxy-3- meth- ylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-Ill and lipoprotein lipase [ J]. FEBS Lett,1999,452(3) : 160-4.
  • 5Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimi- be: pleiotropic and lipid-lowering effects on endothelial function in hu- mans[ J]. Circulation ,2005 , 111 ( 18 ) :2356-63.
  • 6Vrints CJ. Pathophysiology of the no reflow phenomenon[ J]. Acute Card Care,2009,11(2) : 69-76.
  • 7Davignon J. Beneficial cardiovascular pleiotropic effects of statins [J]. Circulation,2004 , 109 (23) : 39-43.
  • 8Cho YK, Hur SH, Han CD, et aL Comparison of ezetimibe/ simvastatin 10/20mg versus atorvastatin 20mg in achieving a target low density lipo- protein-cholesterol goal for patients with very high risk [ J]. Korean Cire J,2011 ,41 (3) :149-53.
  • 9Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel m Guidelines [J]. J Am Coil Cardio1,2004 ,44 (3) : 720-32.
  • 10Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor [J].Cardiovasc Res, 2003, 59 (4): 824-833.

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部